TerminatedPhase 2NCT03081923

Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

Studying Germ cell tumor of testis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Principal Investigator
andrea necchi, MD
Fondazione IRCCS Istituto Nazionale tumori - Milano
Intervention
Durvalumab(drug)
Enrollment
36 target
Eligibility
18-75 years · MALE
Timeline
2017 – 2019

Study locations (1)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03081923 on ClinicalTrials.gov

Other trials for Germ cell tumor of testis

Additional recruiting or active studies for the same condition.

See all trials for Germ cell tumor of testis →

← Back to all trials